SELLAS Life Sciences (SLS) Payables (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Payables for 9 consecutive years, with $4.5 million as the latest value for Q3 2024.
- On a quarterly basis, Payables rose 4.77% to $4.5 million in Q3 2024 year-over-year; TTM through Sep 2024 was $4.5 million, a 4.77% increase, with the full-year FY2023 number at $5.6 million, up 67.98% from a year prior.
- Payables was $4.5 million for Q3 2024 at SELLAS Life Sciences, down from $6.3 million in the prior quarter.
- In the past five years, Payables ranged from a high of $7.4 million in Q1 2024 to a low of $1.8 million in Q3 2020.
- A 5-year average of $3.6 million and a median of $3.1 million in 2023 define the central range for Payables.
- Peak YoY movement for Payables: crashed 53.96% in 2021, then surged 139.01% in 2024.
- SELLAS Life Sciences' Payables stood at $4.7 million in 2020, then tumbled by 53.96% to $2.1 million in 2021, then skyrocketed by 56.58% to $3.4 million in 2022, then skyrocketed by 67.98% to $5.6 million in 2023, then fell by 19.37% to $4.5 million in 2024.
- Per Business Quant, the three most recent readings for SLS's Payables are $4.5 million (Q3 2024), $6.3 million (Q2 2024), and $7.4 million (Q1 2024).